Cannabidiol (CBD) oil has quickly become the new 'cure all' wonder drug with big claims as to what it can achieve but unfortunately not all these claims are back by science. So we decided to get down and dirty with the actual facts about the effects of CBD with out summary of current scientific research on the effects of CBD. There is still alot of work to be done as scientist are just scratching the surface as to what this plant can be used for.
To help you sort out right from wrong, we’ve compiled the most compelling science backed studies on CBD—ranging from the benefits to the potential side effects it may have.
MAIN CONDITIONS TREATED BY PHARMACEUTICAL OR MEDICAL CANNABIS
In Germany, cannabis has been used for many symptoms. However, the only on-label use of cannabis is for multiple sclerosis, and the law does not state clearly what conditions cannabis can be prescribed for. Patients suffering from any condition must prove the condition has so far been unsuccessfully treated with another type of drug. The physician decides, in consultation with the patient, whether to use cannabis or not. This is the case only if the doctor can produce supporting evidence of an effect of medical cannabis on the condition. Therefore, no disease is explicitly excluded. Physicians who prescribe cannabis collect and share data on patients and diagnoses with the BfArM (after one year of therapy or if therapy is discontinued). The following table lists the main conditions that have been treated with medicinal cannabis products, according to the data collected.
Despite the fact that MS is the only condition for on-label use of medical cannabis in Germany, treatment for spasticity (caused by MS) represents fewer than one in ten cases submitted to the BfArM. Symptoms rather than diseases make up the lion’s share of medicinal cannabis patients in the country with the use of cannabis to treat pain accounting for almost seven in ten (69%) users, and nausea accounting for 4% of users.
Eating disorders, such as anorexia, represent a distant third place, accounting for some 8% of cases submitted to the BfArM. Other less widespread uses of medical cannabis include Tourette’s syndrome, ulcerative colitis, ADHD and epilepsy.
“CBD was shown to have anxiolytic, antipsychotic, and neuroprotective properties. In addition, basic and clinical investigations on the effects of CBD have been carried out in the context of many other health conditions, including its potential use in epilepsy, substance abuse and dependence, schizophrenia, social phobia, post-traumatic stress, depression, bipolar disorder, sleep disorders, and Parkinson.”
- 2011: Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action.
- 2012: Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.
- 2014: Cannabinoids for neuropathic pain.
- 2017: Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats.
- 2017: Cannabis as a Substitute for Opioid-Based Pain Medication: Patient Self-Report.
- 2011:Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients.
- 2013: Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?
- 2015: Cannabidiol as a Potential Treatment for Anxiety Disorders.
- 2001: GABAergic mechanisms in epilepsy.
- 2014: Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
- 2017: Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?
- 2018: Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center
- 2004: Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines.
- 2006: Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression.
- 2008: Endocannabinoids in endocrine and related tumours.
- 2010: TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer.
- 2011: Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy.
- 2012: Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1.
- 2012: Cannabidiol inhibits angiogenesis by multiple mechanisms.
- 2013: Cannabidiol as potential anticancer drug.
- 2019: The Potential Clinical Implications and Importance of Drug Interactions Between Anticancer Agents and Cannabidiol in Patients With Cancer